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Abstract
Purpose. Ampli® cation of genetic sequences on chromosome 12q13 is frequently found in soft tissue tumours. However,
for the MDM2 gene, over-expression of the MDM2 protein has not always been shown to accompany gene ampli® cation,
raising the possibility that ampli® cation of genetic sequences targets alternative genes on chromosome 12q13 for
over-expression. To investigate this discrepancy, we have examined 129 soft tissue tumours for ampli® cation of the MDM2
gene using Southern analysis, and 39 of these tumours were also examined by immunohistochemical staining for MDM2
over-expression.
Results. Gene ampli® cation was identi® ed in 14/114 (12.3%) of the malignant tumours, but was not identi® ed in any of
the benign tumours; 21/39 (54%) of the malignant tumours also demonstrated MDM2 over-expression. Within this group
the MDM2 gene was over-expressed in every tumour in which the gene ampli® cation was found, and over-expression in
the absence of gene ampli® cation was also found in an additional 10 tumours.
Discussion. These data demonstrate a clear correlation between the presence of MDM2 ampli® cation and MDM2
over-expression, and provide persuasive evidence therefore that the ampli® cation of genetic sequences on chromosome
12q13 in soft tissue sarcomas targets the MDM2 gene for over-expression. These data also indicate that alternative
mechanisms may contribute to MDM2 over-expression within some tumours.
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Introduction
A variety of mammalian tumour cells contain am-
pli® ed copies of genes whose transforming potential
is then activated by their concomitant over-
expression. In keeping with this, double minute
chromosomes and homogeneously staining regions
have been identi® ed in malignant ® brous histiocy-
tomas, liposarcomas, and alveolar and embryonal
rhabdomyosarcomas.
1± 3 A cluster of genes which
map to chromosome 12q13 have been found to be
ampli® ed and over-expressed in soft tissue sarco-
mas, and include the MDM2, GLI, CDK4,
GADD153 (CHOP) and SAS genes.
4± 8
The MDM2 gene was originally identi® ed as a
dominantly transforming oncogene ampli® ed and
over-expressed from double minute chromosomes in
the 3T3DM cell line.
9 MDM2 was subsequently
shown to cooperate with RAS in the transformation
of primary rat embryo ® broblasts, and to be am-
pli® ed in liposarcomas, malignant ® brous histiocy-
tomas (MFHs) and osteosarcomas.
4 MDM2 has
been shown to bind p53 and inhibit p53-mediated
transactivation
10 and is itself a target for p53-
mediated gene regulation via a cis-acting p53 re-
sponse element in its ® rst intron.
11 Elevated p53
expression results in increased levels of MDM2
mRNA and protein, which in turn binds to and
modulates p53 function. It has now also been shown
that MDM2 can bind and inhibit the growth regula-
tory function of RB1
12 and can activate E2F1/DP1
transcription factors which are involved in promot-
ing entry into the S-phase.
13 The oncogenic activity
of MDM2 may therefore derive from its ability both
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to repress p53 function and to stimulate the activity
of S-phase promoting transcription factors.
A variety of studies have examined MDM2 am-
pli® cation and over-expression in soft tissue tu-
mours.
14± 17 These studies, together with studies on
other tumour types, have demonstrated that MDM2
over-expression as assessed by immunohistochem-
ical staining is frequently found in the absence of
MDM2 gene ampli® cation,
14,18,19 and that MDM2
over-expression may also be absent in tumours in
which ampli® cation has been demonstrated by
Southern analysis.
14 These latter observations raise
the possibility that gene ampli® cation on chromo-
some 12q13 may target a gene or genes other than
MDM2 for over-expression. We therefore sought to
further investigate the role of the MDM2 gene in
soft tissue tumour development by analyzing a large
series of malignant and benign tumours for MDM2
ampli® cation using Southern analysis and scanning
densitometry, and MDM2 and p53 over-expression
was examined in a subgroup of these tumours using
immunohistochemical staining of frozen sections.
Materials and methods
Clinical samples and cell lines
Fresh specimens of primary soft tissue tumours were
obtained during surgical resection from the Royal
Marsden Hospital, London and Surrey, St
Thomas’s Hospital, London and the Royal Ortho-
paedic Hospital, Birmingham. Samples were imme-
diately snap frozen in liquid nitrogen and stored
at 2 70°C until processed. Human cell lines with
the exception of RMS
20 were obtained from the
American Type Culture Collection (ATCC) and
maintained as recommended by their supplier.
Southern analysis
DNA was extracted using a modi® cation of a
method described by Steffen and Weinberg.
21 Ge-
nomic DNA (10 m g) was digested with a three- to
® ve-fold excess of HindIII or EcoRI, subjected to
electrophoresis in 0.8% agarose gels and transferred
to Hybond-N ® lters (Amersham) according to the
manufacturer’s instructions. Filters were hybridized
according to published protocols
22 to a -
32P-labelled
probes prepared using random oligonucleotide
primers.
23 Filters were washed at 65°C to a ® nal
stringency of 0.1 3 SSC, 0.1% SDS.
Ampli® cation of the MDM2 gene was assessed
using a 1.5-kb MDM2 probe prepared by PCR
ampli® cation of reverse-transcribed normal
® broblast RNA using the following primers:
GGGAGCTCCTCGCCACCATGGTGAGGAG-
CAGGCAAATG and GGGGTACCCTCATAG-
ACAGGTCAACTAGGGG. The PCR product was
subcloned into the pBluescript vector and character-
ized by sequencing of its entire length. Following
hybridization to the MDM2 probe, blots were
stripped by immersion in 0.1% SDS at 95°C and
reprobed with pDCC1.0 as a control to correct for
differences between tumour samples in DNA load-
ing and Southern transfer.
4 The DCC gene probe
used was chosen as a control because allele loss at
the DCC locus is found in only around 10% of soft
tissue sarcomas, and homozygous deletion has not
been demonstrated.
24 Allele loss without reduplica-
tion at the DCC locus in tumour DNA would result
in a two-fold overestimation of the degree of
MDM2 ampli® cation, and this error will be intro-
duced in fewer than 10% of the tumours examined.
The degree of ampli® cation was quanti® ed with a
Joyce-Loebel Chromoscan 3 scanning densitometer,
using absorbance at 530 nm. To allow for inaccura-
cies due to the effects of stromal contamination, and
for the non-linear response of the radiographic ® lm,
only samples showing greater than ® ve-fold
ampli® cation were considered to be ampli® ed.
Immunohistochemical staining of tumour specimens for
MDM2 and p53 expression
Two anti-MDM2 mouse monoclonal antibodies
MDM2 (clone IF2) (David Hill, Oncogene Science
Inc.) and SMP14,
25 and the p53 antibody DO1
(Oncogene Science Inc.) were used to stain frozen
sections of primary tumour specimens using a stan-
dard peroxidase-conjugated streptavidin-biotin
method (ABC). Slides omitting the ® rst antibody
were used as negative controls in all cases. Two
tumours known to be positive for either MDM2 or
p53 were included as positive controls in each batch
of staining. The degree of immunostaining was
graded as follows: (negative) , 20% of cells stained
positively, (1 ) 20± 50% of cells stained positively,
(1 1 ) . 50% of cells stain positively.
Results
One hundred and twenty-nine tumours (124 pri-
mary tumours and ® ve cell lines) including 29
leiomyosarcomas, 17 liposarcomas, 16 MFHs, 16
rhabdomyosarcomas, 12 malignant peripheral nerve
sheath tumours (MPNSTs), 10 synovial sarcomas, 3
osteosarcomas, 2 ® brosarcomas, 2 chondrosarco-
mas, 7 other sarcomas, 5 ® bromatoses and 10 be-
nign soft tissue neoplasms were analyzed. Greater
than ® ve-fold ampli® cation of MDM2 was detected
in 14/114 (12.3%) of the malignant tumours but in
none of the ® bromatoses or benign tumours. The
positive samples included 3/16 (19%) MFHs
(STS11, STS41 and STS140), 4/17 (24%) liposar-
comas (STS20, STS44, STS61 and STS131), 2/29
(7%) leiomyosarcomas (STS87 and STS320), 2/16
(12.5%) rhabdomyosarcomas (1 embryonal rhab-
domyosarcoma STS93 and the alveolar rhab-
domyosarcoma cell line RMS), 2/12 (17%)
MPNSTs (STS52 and STS102) and a singleMDM2 ampli® cation and over-expression in sarcomas 19
Table 1. Ampli® cation of the MDM2 gene in soft tissue
tumours
Number Number. Percentage
Tumour type examined ampli® ed ampli® ed
Leiomyosarcoma 29 2 7
MFH 16 3 19
Liposarcoma 17 4 24
Rhabdomyosarcoma 16 2 12.5
MPNST 12 2 17
Synovial sarcoma 10 0 0
Other sarcomas* 14 1 7
Fibromatosis 5 0 0
Benign tumours** 10 0 0
*Includes 3 osteosarcomas, 2 chondrosarcomas, 2
® brosarcomas (one of which showed MDM2 ampli® cation),
1 sarcoma NOS, 2 clear cell sarcomas, 1 der-
mato® brosarcoma proturberans, 1 post-irradiation spindle
cell sarcoma, 1 neuroepithelioma and 1 renal leiomyoblas-
toma.
**Includes 3 haemangiomas, 3 neuro® bromas, 2 neuri-
lemmomas, 1 paraganglioma and 1 angiolipoma.
Fig. 2. Immunohistochemical staining of primary tumours for
MDM2 over-expression. Immunohistochemical staining of
STS24, a high-grade MFH, using the mouse monoclonal
MDM2 antibody MDM2 (IF2) (Oncogene Science). Greater
than 50% of the cells show positive staining for MDM2.
had been selected to include 11 of the tumours with
MDM2 ampli® cation. This group included 8
liposarcomas, 8 MFHs, 6 leiomyosarcomas, 5 MP-
NSTs, 3 rhabdomyosarcomas, 3 synovial sarcomas,
2 sarcomas NOS (not otherwise speci® ed), 1 clear
cell sarcoma, 1 ® brosarcoma and 2 ® bromatoses. Of
these, 21/39 (54%) including 5 MFHs, 4 liposarco-
mas (including STS44 and its recurrence STS162),
3 MPNSTs, 3 rhabdomyosarcomas, 2 leiomyosar-
comas, 2 synovial sarcomas, 1 ® brosarcoma and 1
clear cell sarcoma showed positive immunohisto-
chemical staining for MDM2. An example is shown
in Fig. 2. All 11 of the tumours in which the MDM2
gene was ampli® ed stained positively for MDM2
over-expression, and MDM2 over-expression was
con® rmed in the RMS cell line by Northern analy-
sis. Conversely, the MDM2 gene was ampli® ed in
0/18 (0%) of the negatively staining tumours. Of
the six tumours with strongly positive staining for
MDM2 ( . 50% of cells positive), 5/6 (83%)
demonstrated MDM2 ampli® cation, whereas only
6/15 (40%) of the relatively weakly staining tumours
(20± 50% cells positive) demonstrated MDM2 am-
pli® cation. The level of ampli® cation in weakly
staining tumours was, however, comparable to that
seen in the more strongly staining tumours. Among
® ve additional tumours, for which data regarding
MDM2 gene ampli® cation were not available, over-
expression was identi® ed in two MFHs, STS7 and
STS9.
p53 over-expression, as assessed by immunohisto-
chemical staining, was identi® ed in four tumours. In
two of these tumours, STS24 and STS102, the
MDM2 gene was also over-expressed, and in one of
these tumours, STS102, a malignant peripheral
nerve sheath tumour, MDM2 gene ampli® cation
was found.
® brosarcoma (STS49). These results are presented
in Table 1, and examples of MDM2 gene am-
pli® cation are illustrated in Fig. 1. STS162, a recur-
rence of the liposarcoma STS44, was not included
in the original group of tumours but was subse-
quently analyzed, and also demonstrated MDM2
gene ampli® cation.
Thirty-nine of the tumours analyzed for MDM2
ampli® cation were also examined for MDM2 over-
expression by immunohistochemical staining (Table
2). These tumours were examined without know-
ledge of the MDM2 gene ampli® cation results, but
Fig. 1. Ampli® cation of the MDM2 gene in malignant soft
tissue tumours. Southern blot analysis of EcoRI-digested DNA
probed sequentially with pDCC1.0 and an MDM2 cDNA
probe, demonstrating MDM2 gene ampli® cation in several
tumours. The degree of gene ampli® cation was estimated by using
scanning densitometric analysis of the resulting autoradiographs.
The loading is as follows: lane 1, normal leucocyte DNA; lane
2, RMS cell line; lane 3, STS93; lane 4, STS102; lane 5,
normal leucocyte DNA; lane 6, STS49; lane 7, STS11; lane 8,
normal leucocyte DNA; lane 9, STS41; lane 10, STS44; lane
11, STS61; lane 12, normal leucocyte DNA; lane 13, STS140;
lane 14, STS162; lane 15, normal leucocyte DNA.20 H. Patterson et al.
Table 2. Ampli® cation and/or over-expression of the MDM2 gene in human soft tissue sarcomas
MDM2 gene MDM2 over-
Tumour Histology Grade Source ampli® cation* expression**
STS7 MFH High Recurrence NE 1
STS9 MFH High Recurrence NE 1
STS11 MFH High Recurrence 36 1
STS20 Liposarcoma Low Primary 7 NE
STS23 Pleomorphic High Primary ND 1
rhabdomyosarcoma
STS24 MFH High Recurrence ND 1 1
STS32 Clear cell sarcoma High Primary ND 1
STS34 Leiomyosarcoma High Primary ND 1
STS41 MFH Low Recurrence 14 1
STS44 Liposarcoma High Recurrence 33 1
STS49 Fibrosarcoma Low Recurrence . 50 1 1
STS52 MPNST High Primary 6 1
STS56 MFH High Recurrence ND 1
STS61 Liposarcoma Intermediate Recurrence 44*** 1
STS62 MPNST High Primary ND 1
STS69 Alveolar High Primary ND 1
rhabdomyosarcoma
STS87 Leiomyosarcoma Low Metastasis . 50 1 1
STS93 Embryonal High Metastasis 50 1 1
rhabdomyosarcoma
STS102 MPNST Low Recurrence 20 1 1
STS114 Synovial sarcoma High Primary ND 1
STS117 Liposarcoma High Recurrence ND 1
STS125 Synovial sarcoma High Primary ND 1
STS131 Liposarcoma Low Primary 48 NE
STS140 MFH High Primary 34 1
STS162 Liposarcoma High Recurrence 28 1 1
STS320 Leiomyosarcoma High Primary . 50 NE
RMS Rhabdomyosarcoma Ð Cell line 14 1
1
*Ampli® cation was detected by Southern blot analysis using an MDM2 cDNA probe spanning the whole open reading
frame. Scanning densitometry was used to compare the signal to that obtained with the probe pDCC1.0.
**Detected by immunohistochemical staining of frozen sections with the monoclonal antibody MDM2 (Ab-1) (Oncogene
Science). Staining was graded (1 ) 20± 50% cells stain positively, (1 1 ) . 50% of cells stain positively.
***Problems with DNA degradation and digestion with this sample impair the accuracy of this result.
1 Northern analysis.
NE 5 not evaluated; ND 5 not detected.
Discussion
This study con® rms the observation of ampli® cation
of the MDM2 gene in soft tissue sarcomas which
was ® rst presented by Oliner et al.,
4 and extends the
original observation of MDM2 ampli® cation in
MFHs, liposarcomas and osteosarcomas, to include
leiomyosarcomas, MPNSTs, a primary embryonal
rhabdomyosarcoma and an alveolar rhabdomyosar-
coma cell line (RMS). In contrast to Oliner et al.
4
who detected MDM2 ampli® cation in 36% (17/47)
of their malignant sarcomas, we have detected am-
pli® cation in only 12.3% of this sample of malignant
tumours. These results are, however, in keeping
with the results of Cordon-Cardo et al.
14 who de-
tected a greater than ® ve-fold ampli® cation of the
MDM2 gene in only 15% (11/73) of their sarcomas,
with Forus et al.
7 who detected MDM2 am-
pli® cation in 9% (9/98) of their sarcomas, and with
the results of Ladanyi et al.
26 who detected MDM2
ampli® cation in 14% (4/28) of their high-grade
osteosarcomas.
MDM2 ampli® cation was seen in both high- and
low-grade tumours, as well as in primary, recurrent
and metastatic tumours (Table 2). There did not
appear to be any clear correlation between the de-
gree of ampli® cation and the histological subtype or
grade, or whether the source of the tumour speci-
men was a primary, recurrent or metastatic tumour.
These results indicate that ampli® cation of the
MDM2 gene may be important in the development
of a signi® cant minority of a wide variety of histo-
logical subtypes of malignant soft tissue tumour, but
they provide no support for a role for MDM2 gene
ampli® cation in the development of benign soft
tissue neoplasms, or locally aggressive tumours such
as ® bromatoses.
Whereas only 11/39 of the tumours selected for
MDM2 immunohistochemical staining possessed
MDM2 gene ampli® cation, 21/39 of the tumours in
this subgroup analyzed were immunostain positive
for MDM2 over-expression. Other studies are in
broad agreement with these results. Cordon-CardoMDM2 ampli® cation and over-expression in sarcomas 21
et al.
14 identi® ed MDM2 over-expression in 37%
(76/207) of their sarcomas, with gene ampli® cation
present in only 15% (11/73) of a subset of these
tumours, and Lianes et al.
18 demonstrated MDM2
over-expression in 26/87 human bladder tumours,
but only 1/26 of these tumours demonstrated
MDM2 gene ampli® cation. These results suggest
that mechanisms other than gene ampli® cation may
be important in raising cellular levels of the MDM2
protein; for example, alterations in the stability of
the MDM2 protein, or in the rate of transcription or
translation or of the stability of the MDM2 mRNA.
Only 6/11 of the tumours with MDM2 gene am-
pli® cation reported by Cordon-Cardo et al.
14
showed positive immunohistochemical staining
( . 20% cells positive) for MDM2 over-expression,
raising the possibility that in some sarcomas the
target for gene ampli® cation on chromosome
12q13 may not be MDM2. The results presented
here, however, have demonstrated that MDM2
ampli® cation accurately predicts for MDM2 over-
expression. This complete correlation is corrobor-
ated by three other studies with soft tissue tumours.
Leach et al.
15 identi® ed MDM2 gene ampli® cation
and MDM2 over-expression in 8/24 MFHs and
liposarcomas, Florenes et al.
16 demonstrated MDM2
gene ampli® cation and over-expression in 10/98
bone and soft tissue tumours, and Nakayama et al.
17
identi® ed MDM2 gene ampli® cation, and over-
expression by Northern analysis, in each of 11/48
soft tissue tumours. These observations, the demon-
stration that MDM2 inhibits transactivation by the
product of the p53 gene (a gene known to contri-
bute to the neoplastic process in sarcomas) and the
demonstration that MDM2 is a dominantly trans-
forming oncogene
9 provide strong evidence in fa-
vour of a role for MDM2 ampli® cation and
over-expression in the genesis of a subgroup of soft
tissue sarcomas.
We have identi® ed over-expression of both p53
and MDM2 in two tumours, STS24 and STS102,
one of which possessed MDM2 gene ampli® cation.
The status of the p53 gene in these two tumours has
not been examined. However, when similar ® ndings
have been demonstrated in other tumours,
16,18 over-
expression of the MDM2 protein was accompanied
by over-expression of wild-type and not mutant p53
protein. For example, Landers et al.
27 examined
choriocarcinoma cell lines and found over-
expression of both wild-type p53 and MDM2. The
over-expression of MDM2 was not explained by
gene ampli® cation, elevated transcription or altered
protein stability, but appeared to have resulted from
increased protein translation. In addition to these
observations, the level of MDM2 transcription is
known to be regulated by the expression of wild-
type p53.
11 Additional data regarding the status of
the p53 gene were available for 38 of the tumours
examined for MDM2 gene ampli® cation
(29 leiomyosarcomas, 4 cell lines, 1 primary rhab-
domyosarcoma, 2 MFHs, 1 liposarcoma and 1 post-
irradiation spindle cell tumour), and nine of these
had also been examined for MDM2 over-
expression. Thirteen tumours possessed p53 muta-
tions, seven had undergone homozygous rearrange-
ment of the p53 gene and six had mis-sense point
mutations.
24,28 Two of these tumours, STS7, an
MFH, and STS117, a liposarcoma, both of which
had undergone homozygous rearrangement at the
p53 locus, also demonstrated MDM2 over-
expression. In STS117 the over-expression was
found in the absence of gene ampli® cation. The
status of wild-type p53 protein expression in tumour
cells may, therefore, modulate the level of MDM2
protein expression, thus providing a mechanism for
MDM2 over-expression in the absence of gene am-
pli® cation in a subgroup of tumour cells.
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